<DOC>
	<DOCNO>NCT00787371</DOCNO>
	<brief_summary>In patient chronic hepatitis C , ultimate treatment goal improvement liver histology inhibition progression liver cirrhosis hepatocellular carcinoma ( HCC ) . These effect report correlated sustained ALT improvement . Therefore , aim study determine low-dose ( 0.25 , 0.5 , 1.0 mcg/kg SC QW ) PegIntron monotherapy administer 12 week result ALT normalization Japanese patient chronic hepatitis C .</brief_summary>
	<brief_title>Effect Low-dose PegIntron ALT Normalization Japanese Patients With Chronic Hepatitis C ( Study P04508 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients chronic hepatitis C patient ( CHC ) meet follow criterion : At least 20 year age willing sign inform consent Patients practice contraception Patients classify either relapsers nonresponders . Weight 45 100 kg Patients willing hospitalized 3 day start treatment Patients positive HCVRNA Serum ALT level : Over 60 IU/L , equal less 150 IU/L Neutrophil count : equal 1,200 /mm^3 Platelet countï¼šequal 100,000/mm^3 Patients condition would interfere evaluation therapeutic efficacy study drug patient assurance safety concern exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>alanine transaminase</keyword>
</DOC>